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The term cirrhosis-associated immune dysfunction refers to the
main syndromic abnormalities of immune function, immunodeﬁ-
ciency and systemic inﬂammation that are present in cirrhosis.
The course of advanced cirrhosis, regardless of its aetiology, is com-
plicated by cirrhosis-associated immune dysfunction and this con-
stitutes the pathophysiological hallmark of an increased
susceptibility to bacterial infection, distinctive of the disease.
Cirrhosis impairs the homeostatic role of the liver in the systemic
immune response. Damage to the reticulo-endothelial system com-
promises the immune surveillance function of the organ and the
reduced hepatic synthesis of proteins, involved in innate immunity
and pattern recognition, hinders the bactericidal ability of phago-
cytic cells. Systemic inﬂammation, in form of activated circulating
immune cells and increased serum levels of pro-inﬂammatory cyto-
kines, is the result of persistent episodic activation of circulating
immune cells fromdamage-associatedmolecular patterns, released
fromnecrotic liver cells and, as cirrhosis progresses, frompathogen-
associated molecular patterns, released from the leaky gut.
Cirrhosis-associated immune dysfunction phenotypes switch from
predominantly ‘‘pro-inﬂammatory’’ to predominantly ‘‘immunode-
ﬁcient’’ in patients with stable ascitic cirrhosis and in patients with
severely decompensated cirrhosis and extra-hepatic organ failure
(e.g. acute-on-chronic liver failure), respectively. These cirrhosis-
associated immune dysfunction phenotypes represent the
extremes of a spectrum of reversible dynamic events that take
place during the course of cirrhosis. Systemic inﬂammation canJournal of Hepatology 20
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GALT, gut-associated lymphoid tissue; MLN, mesenteric lymph node.affect the functions of tissue somatic cells and modify the clinical
manifestation of cirrhosis. The best characterized example is the
contribution of systemic inﬂammation to the haemodynamic
derangement of cirrhosis, which correlates negatively with
prognosis.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
The immune system plays a dual role in the pathogenesis of
cirrhosis such that, besides the role of immune-mediated inﬂam-
matory mechanisms, cirrhosis itself also leads to immune system
dysfunction. The immune system mediates hepatocyte damage
due to alcohol, virus infection or autoimmunity, driving ﬁbrogen-
esis through hepatic stellate cell activation. In addition, cirrhosis
leads to impairment of the immune system with an inability to
protect the host from bacterial infection and dysregulated
immune cell activation.
This paper reviews the myriad of dynamic detrimental effects
that cirrhosis has on the immune system that we have designated
cirrhosis-associated immune dysfunction (CAID). This concept
includes two main syndromic alterations: (i) immunodeﬁciency,
due to an impaired response to pathogens at different levels of
the immune system, and (ii) systemic inﬂammation, as a conse-
quence of persistent and inadequate stimulation of cells of the
immune system (Fig. 1). CAID should be considered a complica-
tion of cirrhosis of any aetiology. It accounts for many distinctive
features of cirrhosis such as a predisposition to bacterial infection
and a poor response to vaccination [1–3]. It may also play an
important role in endothelial activation and the haemodynamic
disturbance of cirrhosis and contributes to other clinical manifes-
tations, such as asthenia.Contribution of the liver to the systemic homeostasis of the
immune system
The liver regulates homeostasis of the immune system through
two mechanisms. First, it plays a role in immune surveillance,
defending against blood-borne pathogens via its double blood14 vol. 61 j 1385–1396
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• Cirrhosis-associated immune dysfunction refers to both 
immunodeficiency and systemic inflammation that occur 
in cirrhosis
• Immunodeficiency in cirrhosis results from damage 
to the local immune surveillance function of the liver, 
reduced synthesis of pattern recognition receptors, and 
damage at the systemic level of immune response cell 
function
• Systemic inflammation accompanies immunodeficiency 
and is attributed to persistent immune cell stimulation 
as well as to PAMPs and DAMPs from a leaky gut and a 
damaged liver, respectively. Inflammation is reflected by 
an increased production of pro-inflammatory cytokines, 
their enhanced serum levels, and the upregulated 
expression of cell activation markers
• The cirrhosis-associated immune dysfunction 
phenotypes represent the extremes of a spectrum of 
reversible dynamic events that take place during the 
course of cirrhosis. Under constant PAMPs challenge, 
the immune response pattern in cirrhosis switches 
from a predominantly “pro-inflammatory” phenotype 
in patients with “stable” decompensated cirrhosis to a 
predominantly “immunodeficient” one in patients with 
severely decompensated cirrhosis and extra-hepatic 
organ failure (e.g. ACLF)
• Systemic inflammation can affect the function of 
tissue somatic cells and modify the clinical expression 
of cirrhosis. The best example is the contribution 
of systemic inflammation to the haemodynamic 
derangement of cirrhosis, which correlates negatively 
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supply, thereby avoiding the systemic spread of microbial and
dietary antigens arriving from the gut [4]. This function of the
liver is offset by the local immune tolerance to non-pathogenic
exogenous material [5]. The second mechanism, used by the liver
to drive homeostasis of the immune system, is the synthesis of
soluble molecules that are essential for an effective immune
response [6].
Immune surveillance: Role of the liver
The liver exerts its antimicrobial surveillance function through
different populations of resident antigen presenting cells and
lymphocytes. These are organized in a manner speciﬁcally
designed to maximize screening for both systemic and gut-
derived pathogens. The liver antigen presenting cells include
Kupffer and sinusoidal endothelial cells, which comprise the ret-
iculo-endothelial system of the liver, and dendritic cells. Kupffer
cells reside within the sinusoidal vascular space and represent
the largest group of ﬁxed macrophages in the body, and sinusoi-
dal endothelial cells form a sieve-like, fenestrated endothelium.
Unlike macrophage populations of other organs, Kupffer cells
occur on the intraluminal side of the vasculature and can cap-
ture bacteria under ﬂow conditions. Kupffer cells are specialized
at eliminating insoluble waste by phagocytosis through a vari-
ety of receptors. As such, Kupffer cells are endowed with unique1386 Journal of Hepatology 2014complement receptors that can bind avidly to complement
component 3b (C3b) under shear conditions [7]. Sinusoidal
endothelial cells are responsible for the elimination of soluble
macromolecules and colloidal waste by endocytosis. Kupffer
and sinusoidal endothelial cells are also antigen presenting cells,
constitutively expressing MHC class I and II and co-stimulatory
receptors in addition to molecules that promote antigen uptake,
including mannose and scavenger receptors [8,9]. Despite Kupf-
fer cells being critical for microbial capture, their role in micro-
bial killing seems to be dependent on the nature of the
pathogen and on the recruitment of additional immune cells
to the liver [10]. The liver also contains several populations of
dendritic cells, which characteristically have a reduced capacity
to drive the activation of T cells, in part due to both, their
‘‘immature’’ development status, and to the local cytokine
milieu of the liver, including high interleukin (IL)-10 and low
IL-12 levels [11].
Additionally, the liver contains populations of both resident
and transiting T and B lymphocytes scattered throughout the
parenchyma and the portal tracts that are important in the defen-
sive adaptive immune response. Further, the liver is enriched in
natural killer (NK) cells and unconventional lymphocytes (natural
killer T and cd T cells), which have roles in innate immune
responses of the liver.
Besides conferring strong local innate immunity, the liver is a
major site of induction of local and systemic adaptive immune
responses, mediated by T lymphocytes, playing a critical role in
the homeostatic regulation of the immune system. The delicate
balance between immunity and tolerance, observed in the liver,
is driven by several mechanisms. In the speciﬁc antigen challeng-
ing micro-environment of the liver, tolerance is maintained
through: (i) the direct access of naive CD8+ T cells to antigen
presenting cells in the absence of CD4+ T cell activation [12],
(ii) the constitutively low abundance of MHC expression by
liver-resident cells [13], and (iii) high IL-10 production by Kupffer
and sinusoidal endothelial cells [14]. All these mechanisms pro-
mote the non-activation and/or apoptosis of CD4+ T lymphocytes.
Further, the expression of adhesion molecules facilitates the
sequestering of circulating activated T cells, particularly CD8+ T
cells, by the liver endothelium [4].Relevance of the liver in the systemic immune response
The liver, primarily through its hepatocytes, is a major source of
proteins involved in innate and adaptive immune responses,
including complement components and many secreted pattern-
recognition receptors (PRRs) [15]. Complement proteins play
roles in the regulation and effector stage of the immune response,
and their activation gives rise to a wide range of opsonic,
inﬂammatory and cytotoxic activities. The liver is also the main
source of soluble PRRs (e.g. C reactive protein, lipopolysaccharide
[LPS]-binding protein [LBP], peptidoglycan-recognition protein,
soluble CD14), which activate complement, induce opsonization
and regulate immune cell function [16,17]. The liver also
produces other acute phase proteins, such as hepcidin, ﬁbrinogen
and proteinase inhibitors, which participate in the innate
immune response and in controlling tissue damage and repair
during inﬂammation. Hepatocytes synthesize and secrete most
of these proteins in response to different pro-inﬂammatory cyto-
kines (e.g. TNFa, IL-6), generated in the course of a systemic
inﬂammatory responses.vol. 61 j 1385–1396
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Fig. 1. Cirrhosis-associated immune dysfunction. Under bacterial challenge, in a healthy individual, antigen recognition (in red) and immune cell activation (in green) are
tightly coordinated to mount an effective immune response against the pathogen. Cirrhosis progression from compensated to decompensated and then to further
decompensated disease, i.e. acute-on-chronic liver failure (ACLF), is associated with mechanisms of mainly hepatic insufﬁciency and PAMPs- and DAMPs-driven
stimulation. These mechanisms impair the regulatory and the effector immune response. In compensated cirrhosis, still in the absence of gut bacterial translocation, DAMPs
released from necrotic hepatocytes may initiate activation of the immune system and sterile systemic inﬂammation (continuous green line). At the decompensated stage,
the persistent episodic translocation of bacterial products, e.g. endotoxin, drives further the activation of the immune system, involving increased serum levels of pro-
inﬂammatory cytokines and augmented surface expression of activation antigens on immune cells. The predominantly ‘‘pro-inﬂammatory’’ CAID phenotype occurs in
response to continuous PAMPs signalling and downregulation of anti-inﬂammatory cytokines and negative feedback mechanisms (e.g. IL-10, IRAK-M, GSK3b) (dotted green
line). In addition, progressive immunodeﬁciency occurs in ‘‘stable’’ decompensated cirrhosis, as a result of different mechanisms, including loss of the liver immune
surveillance function, and impaired immune cell functions, such as phagocytosis ability (red line). At the terminal stage of cirrhosis, under persistent PAMPs pressure, the
immune response is exhausted and the CAID phenotype switches to a predominantly ‘‘immunodeﬁcient’’ phenotype of impaired innate and adaptive protective immune
responses.
JOURNAL OF HEPATOLOGYIn addition, liver cells express different membrane-bound or
cytoplasmic PRRs, which recognize different bacterial and viral
molecules. These include cell surface and endosomal toll-like
receptors (TLRs), cytoplasmic nucleotide-binding oligomerization
domain (NOD)-like receptors (NLRs), and RNA helicases.
Interactions of these PRRs with their ligands in immune cells
cause regulatory signals and activation, which in the speciﬁc case
of bacterial products promotes NF-jB activation. The constitutive
expression and low-level stimulation of these molecular systems
is characteristic of the liver [18]. Speciﬁcally, TLR4 is expressed
on all types of liver cells and is likely involved in the
uptake and clearance of endotoxins, and the production of
pro-inﬂammatory and anti-inﬂammatory cytokines.Cirrhosis-induced immunodeﬁciency
Cirrhosis is associated with several abnormalities in innate and
adaptive components of the immune system’s response to micro-
bial challenge, leading to a state of acquired immunodeﬁciency
(Fig. 2).Journal of Hepatology 2014Damage to the liver’s immune surveillance function
The immune surveillance function of the liver is compromised by
a reticulo-endothelial system, damaged by sinusoidal ﬁbrosis and
capillarization, septal ﬁbrosis with portal-systemic shunts, and
Kupffer cell loss or damage [4]. This structural derangement
reduces the clearance of endotoxin and bacteria from the blood,
leading to bacteremia, metastatic organ infection, and persistent
immune system stimulation. A lack of Kupffer cells or of their
complement receptors results in uncontrolled bacteraemia and
increased host death in experimental models [19]. In agreement
with these experimental ﬁndings, diminished reticulo-endothelial
system function in cirrhosis has been associated with a greater
risk of bacterial infection and lower survival [20].
Cirrhosis impairs the synthesis of innate immunity proteins
and of PRRs, reducing the bactericidal capacity of phagocytic cells.
Given the large functional reserve of the liver, lowered serum lev-
els of these proteins are only evident in patients with advanced
cirrhosis and ascites. Indeed, ascites due to cirrhosis increases
the susceptibility to bacterial infection. This has been related to
low opsonic activity as a result of reduced concentrations of C3,vol. 61 j 1385–1396 1387
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Fig. 2. Cirrhosis-induced immunodeﬁciency. Cirrhosis disrupts the architecture and cellular organization of the liver and diminishes the hepatic ability to synthesize
proteins. These events compromise the immune surveillance function of the liver through damage of the reticulo-endothelial system and synthesis of innate immunity
proteins and PRRs. Besides, cirrhosis affects the functions of circulating and intestinal populations of immune cells. Thus, immunodeﬁciency is the result of a panoply of
abnormalities provoked by cirrhosis that affect cellular and soluble components of the immune response both at the liver and systemically.
ReviewC4 and CH50 in the serum and ascitic ﬂuid [21,22]. The defensive
relevance of PRRs synthesized by the liver is also highlighted by
the fact that cirrhotic patients with a gene polymorphism, confer-
ring them low serum levels of the recognition molecule mannose-
binding lectin, or transplant recipients of a liver with this
polymorphism, show an increased risk of bacterial infection
[23,24].
Circulating immune cell damage
Besides modifying the local immune surveillance function of the
liver and PRR synthesis, cirrhosis also compromises immune cell
functions at the systemic level. Characterizing immunodeﬁ-
ciency, associated with cirrhosis, requires the systematic study1388 Journal of Hepatology 2014of the main circulating populations of immune cells. The abnor-
malities in these populations described so far are:
1. Neutrophils. Besides being reduced in number due to
sequestration by the spleen, the most commonly reported defect
is the impaired phagocytosis of opsonized bacteria [25–28].
Accordingly, these cells show defective superoxide anion O2- pro-
duction andmyeloperoxidase activity and a lower response to the
peptidoglycan recognition protein [25,29,30], which impairs their
microbicidal capacity. These defects seem to be the result of
intracellular signalling alterations, including impaired phosphor-
ylation of a major NADPH oxidase 2 component, p47-phox
(S345), by mitogen-activated protein kinases or defective
phosphatidylinositol speciﬁc phospholipase C [29,30]. Neutrophils
also show impaired chemotaxis to the infection focus, throughvol. 61 j 1385–1396
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reduced adhesion to microvascular endothelial cells and
decreased transendothelial migration [27,31]. Of note, and as for
other circulating immune cells, neutrophil dysfunction has been
linked to persistent in vivo stimulation, as shown by its increased
resting respiratory burst, especially observed in patients with
higher serum levels of pro-inﬂammatory cytokines [27].
2. Monocytes. Cirrhosis alters the number, subset distribution
and function of circulating monocytes. In contrast to the
frequently observed leukopenia, cirrhosis is associated with mon-
ocytosis, as the main increase is in a pro-inﬂammatory non-clas-
sical CD14+CD16+ subset of monocytes [32,33]. The expansion of
these monocytes with limited phagocytic activity is observed
regardless of the aetiology but not of the severity of cirrhosis
[33,34]. A study has demonstrated the impaired function of the
circulating monocyte Fc-c receptor, which is needed for clearance
of IgG coated bacteria in patients with cirrhosis, developing
bacterial infection [35]. Remarkably, circulating monocytes are
in vivo activated in cirrhosis, as further discussed below.
3. B lymphocytes are profoundly affected in cirrhosis. In
patients with alcoholic or HCV cirrhosis, diminished B cell fre-
quencies and peripheral blood absolute counts have been
reported [36–39]. The most striking anomaly observed in the B
cell compartment is memory B cell dysfunction. Speciﬁcally, cir-
rhosis leads to a loss of CD27+ memory B cells, a subset generated
in response to T cell-independent antigens, which show hypore-
sponsiveness to CD40/TLR9 activation, impaired upregulation of
co-stimulation markers as well as impaired TNFb and IgG produc-
tion and T cell allostimulation [39].
4. T lymphocytes. Recent ﬁndings have suggested a disruption
of the T cell compartment in cirrhosis. T cell lymphopenia is com-
mon in cirrhosis and affects T helper (Th) and cytotoxic T cells
(Tc) [34,40–42]. T cell depletion is more pronounced in the naive
than in the memory compartment, regardless of disease aetiol-
ogy, and is evident since the early stages of cirrhosis [34,43,44].
Retraction of the T cell compartment results from: (i) impairment
in the de novo production of new naive T cells due to accelerated
aging and atrophy of the thymus, (ii) reduction of the T cell mem-
ory subset, due to spleen sequestration and cell consumption,
related to activation-driven bacterial translocation and increased
apoptosis, and (iii) impaired compensatory peripheral prolifera-
tion [43]. Additionally, circulating T lymphocytes are in vivo
activated and show diminished proliferation [45–47].
5. Circulating NK cells are also defective in cirrhosis and show
a poor response to cytokine stimulation [48]. These ﬁndings are
also strikingly evident at the intrahepatic level, where NK cells
play an important role in alleviating liver ﬁbrogenesis [49].Gut-associated lymphoid tissue (GALT) damage
Another immune system compartment that is also profoundly
affected in cirrhosis is GALT, which constitutes the ﬁrst barrier
of defence against antigens and pathogens entering the organism
from the intestine. The intestinal lymphoid tissue, distributed in
Peyer’s patches and mesenteric lymph nodes (MLN), acts by
inducing immunity and tolerance, whereas its effector sites are
scattered throughout the lamina propria and mucosal epithelium.
In cirrhosis, GALT is under the constant pressure of pathological
bacterial translocation and the increased passage of bacterial
products that results from a leaky gut and an elevated enteric
bacterial load. The consequence of this persistent stimulation is
an increased number of activated monocytes, dendritic cellsJournal of Hepatology 2014and T lymphocytes at the intestine and MLN [50–53]. In turn,
these activated cells cause the augmented expression of
pro-/anti-inﬂammatory cytokines at the lamina propria, mucosal
epithelium and MLN, as well as increased phagocytosis by intes-
tinal dendritic cells [50–52]. Bowel decontamination with non-
absorbable antibiotics reduces the number of activated immune
cells in the intestinal lamina propria and MLN [50–53]. This
supports the pathogenetic role of enteric bacteria in intestinal
inﬂammation.
The ﬁrst major consequence of intestinal and MLN inﬂamma-
tion in cirrhosis is systemic inﬂammation. As described later, as
cirrhosis progresses, the gut becomes a major source of activated
immune cells and pro-inﬂammatory cytokines, promoting and
maintaining a systemic inﬂammation [34,50]. In addition, this
intestinal inﬂammation might perpetuate intestinal barrier fail-
ure. It is tempting to speculate that the increased pro-inﬂamma-
tory cytokine production (e.g. TNFa, IFNc, IL-6) by intestinal
immune cells disrupts epithelial tight-junctions and favours fur-
ther increased translocation of bacteria and bacterial products,
creating a vicious circle. Indeed, a recent study has correlated
increased activated macrophages in the duodenal lamina propria,
augmented intestinal permeability, and altered intestinal tight-
junction protein expression in patients with decompensated cir-
rhosis [54]. Besides intestinal immune cell damage, the ﬁndings
of several experimental models of chronic liver damage point to
deﬁciencies in the production of intestinal antimicrobial pep-
tides, such as a-defensins and RegIII proteins. These peptides
are needed to maintain microbiota-host homeostasis, and their
deﬁciency could induce intestinal dysbiosis and bacterial translo-
cation [55,56].Cirrhosis-induced systemic inﬂammation
A distinctive feature of CAID in cirrhosis is the dynamic coexis-
tence of acquired immunodeﬁciency and systemic inﬂammation.
The latter results from the persistent stimulation of immune cells
and is deﬁned by increased production and enhanced serum
levels of pro-inﬂammatory cytokines and the upregulated
expression of cell activation markers.
Evidence of systemic inﬂammation
As shown in Table 1, the in vivo activation of circulating immune
cells in cirrhosis is supported by the presence of: (i) neutrophils,
showing an increased respiratory burst and enhanced expression
of CD11b [27,31], (ii) monocytes, featuring the enhanced surface
expression of HLA-DR and activation/co-stimulatory molecules
CD80 and CD86, as well as the upregulation of pathways and
the increased production of pro-inﬂammatory cytokines (e.g.
TNFa, IL-6) [34,50,52,57,58], (iii) T lymphocytes, showing an
increased surface expression of activation antigens that are
polarized to augmented IFNc, TNFa, and IL-17 production
[34,50,59,60], and (iv) B lymphocytes, showing an upregulation
of the activation/co-stimulatory markers, HLA-DR and CD86,
and an increased responsiveness to cytokines and hyperglobulin-
emia [61,62].
Activated circulating immune cells eventually become
major contributors to increased serum concentrations of pro-
inﬂammatory cytokines such as TNFa, TNFa soluble receptors I
and II, IL-1b, IL-6 and IFNc, IL-17, as well as ICAM-1 and
VCAM-1, present in experimental and human cirrhosisvol. 61 j 1385–1396 1389
Table 1. Evidences supporting persistent systemic inﬂammation in cirrhosis.
Finding [References]
Neutrophils with increased respiratory burst [27]
Increased expression of surface antigens of activation/co-stimulation on circulating immune system cells (i.e., 
CD11b on neutrophils, HLA-DR or CD80/86 on antigen presentation cells, CD134 on T cells, loss of CD62L or 
of CD45RC on T cells)
[31,34,50-53]
Increased production of pro-inflammatory cytokines (TNFα, IFNγ, IL-17) by circulating immune system cells 
(monocytes, T cells, B cells)
[34,50,59-61,66]
Increased serum levels of pro-inflammatory cytokines (TNFα, IL-1β, IL-6, IL-17, IL-18, IFNγ) or receptors 
(sTNFRI, IL1sRI, IL1Ra, sCD14, Fas-R)
[34,50,59,63-81]
Increased serum levels of acute phase reactants (LBP, CRP) [34,63,64,69-71,76,77,80]
Increased serum levels of molecules of endothelial activation (ICAM-1, VCAM-1, VEGF, nitrates/nitrites) [34,69,70,76,79,80,88,89]
Review[34,50,59,63–81]. Speciﬁcally, monocytes are a major source of
circulating TNFa in cirrhosis, as shown by the direct correlation
observed between serum levels of this critical effector cytokine
and the TNFa production capacity of monocytes [34]. The sever-
ity of this state of systemic inﬂammation parallels that of cirrho-
sis itself, as assessed by the Child-Pugh score [63,65,71,78,80–
83], and is particularly intense in cirrhosis with ascites
[34,50,84]. It is important to point out that the ﬁnal biological
expression of the cytokine network depends on the balance
between serum cytokine levels and those of their inhibitors, such
as the soluble forms of cytokine receptors. The intense immune
system dysregulation of cirrhosis involves a concomitant increase
in serum cytokines (i.e. TNFa, IL-6) and in their soluble receptors
(i.e. sTNFRI, sTNFRII, sgp130). In effect, cirrhosis has been associ-
ated with the enhanced serum expression of the soluble form of
the IL-6 receptor, sgp130, which is a potent inhibitor of IL-6 sig-
nalling [85]. This could explain the resistance to IL-6, shown by
patients with cirrhosis, and the resultant acute phase response
to this cytokine [86,87].
Aetiopathogenesis of systemic inﬂammation
In advanced cirrhosis, the immune response leading to systemic
inﬂammation is initiated when bacteria from the intestinal
lumen reach the internal milieu (i.e. gut bacterial translocation).
Pathogen-associated molecular patterns (PAMPs) from enteric
bacterial organisms and/or damage-associated molecular
patterns (DAMPs), originating from the host tissue upon injury,
recognize PRRs, expressed on innate immune cells. Notably, not
only live bacteria, but also the episodic, persistent inﬂow of
PAMPs (including LPS, lipopeptides, glycopolymers, ﬂagellin and
bacterial DNA) into the hepato-splanchnic circulation contributes
to the systemic inﬂammatory response [84,88–91] (Fig. 3).
Immune recognition of bacteria and PAMPs in cirrhosis takes
place both locally in the GALT and MLN and in the peripheral
blood [50,52,92]. Furthermore, immune cells already activated
in the GALT and MLN may enter the peripheral blood and spread
the inﬂammatory response systemically [50,52].
Upon interaction, PRRs trigger a transcriptional response lead-
ing to gene expression and to the synthesis of a broad range of
molecules, including numerous pro- and anti-inﬂammatory cyto-
kines, chemokines, cell adhesion molecules, and immunorecep-
tors that induce a panoply of cellular- and counter-responses,
driving the adaptive immune response (Table 1). Further conse-
quences of the PRRs’ mediated immune cell activation responses
include, but are not limited to, enhanced phagocytic activity [27],1390 Journal of Hepatology 2014vascular endothelial injury [34,69,70,76,79,80,88,89,92], synthesis
of acute phase proteins by the liver [34,63,64,69–71,76,77,80],
chemotaxis of leukocytes to the sites of inﬂammation, mainly
the liver, and activation of leukocytes at the systemic level. The
expression of PRRs, such as TLRs or NLRs, is distinctively upregu-
lated on cells of the innate immune system in cirrhosis with
ascites [27,93,94].
The increased translocation rate of enteric bacteria and/or
their products is also a distinctive feature of advanced cirrhosis
[95–97], arising from the breakdown of three interrelated levels
of defence that constitute the intestinal barrier. Speciﬁcally,
cirrhosis leads to increased intestinal permeability, due to
compromised epithelial integrity, intestinal bacterial overgrowth
and dysbiosis, caused by disruption of host microbiota homeosta-
sis and intestinal and general immune defence impairment
[97,98]. Concurrent damage to these three levels of defence
explains the referred high rate of translocation of live bacteria
and PAMPs from the gut that occurs in advanced human and
experimental cirrhosis [34].
The contribution of enteric bacteria and PAMPs to the patho-
genesis of immune cell activation and the inﬂammatory state of
cirrhosis is supported by several ﬁndings: (i) the degree of expan-
sion of activated monocytes, activated Th cells and memory B
cells in the peripheral blood can be correlated with the presence
of surrogate markers of bacterial translocation, such as increased
LBP or sCD14 in the serum of patients with cirrhosis and ascites
[34,39,84]. Similarly, the critical role of bacterial translocation,
driving immune cell activation and inﬂammatory responses in
cirrhosis, is supported by the correlation between bacterial
growth in the MLN and the pro-inﬂammatory phenotype of circu-
lating monocytes and T lymphocytes in cirrhotic rats with ascites
[50]. In addition, elegant ex vivo experiments of TLR2 and TLR4
blockade or endotoxin removal abrogated B cell activation and
neutrophil phagocytic dysfunction of cells from healthy donors,
induced by plasma from patients with cirrhosis, respectively
[27,39]. (ii) The expansion of B lymphocytes is restricted to
clones that are responding to pathogens, as identiﬁed by the pref-
erential increase of antibodies against Saccharomyces cerevisiae,
Gala1-3Galb1-3GlcNAc, a glycan epitope found in the bacterial
cell wall galactosamine, or complex gut bacterial protein lysates
[99–102]. And ﬁnally, (iii) the suppression of enteric aerobic bac-
terial load and gut bacterial translocation by intestinal decontam-
ination with antibiotics normalizes the expansion of circulating
activated immune cells and attenuates the pro-inﬂammatory
cytokine production in MLN and blood in experimental models
and in patients with cirrhosis and ascites [34,50,84].vol. 61 j 1385–1396
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Fig. 3. Pathogenesis of systemic inﬂammation in cirrhosis. Host immune cells are stimulated by bacteria and pathogen-associated molecular patterns (PAMPs), produced
and released from a leaky gut, and damage-associated molecular patterns (DAMPs), released from necrotic liver cells. These stimuli activate host pattern recognition
receptors, such as the toll-like receptor (TLR) and the nucleotide-binding oligomerization domain-like receptors (NLRs). Activation of these receptors leads to expression of
activation surface molecules (cytokine receptors, adhesion molecules) on immune cells and upregulation of cytokines (pro- and anti-inﬂammatory lymphokines and
monokines), chemokines and growth factors, which are released to recruit and activate additional inﬂammatory cells. Pattern recognition receptor (PRR)-dependent
immune cell activation in cirrhosis occurs locally in the gut-associated lymphoid tissue (GALT), mesenteric lymph nodes (MLN), and in peripheral blood. Immune cells
already activated in the GALT and MLN may enter the peripheral blood and further spread systemically the inﬂammatory response.
JOURNAL OF HEPATOLOGYDAMPs and sterile particulates, released from necrotic hepa-
tocytes, might also contribute to elicit an inﬂammatory response
in cirrhosis [103]. Sterile inﬂammation, induced by DAMPs, is
evident in the acute hepatic injury by acetaminophen, during
ischemia/reperfusion, and in the low-chronic hepatic injury by
alcoholic and non-alcoholic steatohepatitis [104–106]. Due to
the size of the liver and the extent of its damage in cirrhosis, it
is tempting to speculate that a signiﬁcant amount of DAMPs from
necrotic hepatocytes could spill to the circulation in cirrhosis of
any aetiology and contribute to immune cell activation (Fig. 3).
Indeed, systemic inﬂammation is already present, albeit at a
lower grade, in the pre-ascitic stage of human and experimental
cirrhosis, when bacterial translocation is not yet critical
[52,71,84]. In this regard, the hepatic lymph nodes, and not the
gut, are the main source of activated circulating immune cells
in rats with pre-ascitic cirrhosis, as shown by correlates between
their frequencies in hepatic lymph nodes and peripheral
blood [52].
As in other inﬂammatory conditions, genetic polymorphisms
of cytokines and innate immunity pathways may lead to varying
immune responses and bacterial infection susceptibilities in
cirrhosis. Well-established correlates between intestinal and sys-
temic immune responses and bacterial infections in cirrhosis
have been demonstrated through variations in the genes coding
for PRRs. Speciﬁcally, NOD2 and TLR2 variants impair innate host
defence mechanisms, leading to increased SBP susceptibility and
mortality in cirrhosis [107–111].Journal of Hepatology 2014Dynamic pattern of the CAID phenotypes
The response of the immune system to antigens and/or activation
signals is characterized by a dynamic pattern of cellular activa-
tion and differentiation, as well as amounts and types of cytokine
and antibody secretion. Temporal variations exist in the internal
mechanism of immune response regulation that are also
modulated by environmental and activation challenge features.
A well-known mechanism that is triggered to regulate the
pro-inﬂammatory environment is endotoxin tolerance, whereby
monocytes, persistently exposed to low endotoxin concentra-
tions, enter into a transient state of unresponsiveness to further
endotoxin challenge [112].
The dynamic immune response pattern is clearly manifested
in CAID. Indeed, the immune disturbance of cirrhosis varies
according to disease stage (compensated, decompensated,
acute-on-chronic liver failure [ACLF]), the extent of liver injury,
and the presence of environmental stimulation, induced by
signalling from persistent episodic bacterial translocation.
The immune system in patients and experimental models of
‘‘stable’’ decompensated cirrhosis faces the frequent challenge
of different types and intensities of PAMPs originated in the gut
(Figs. 1 and 3). In this setting, the immune system exhibits a
predominantly ‘‘pro-inﬂammatory’’ phenotype, with increased
expression of activation antigens on immune cells, and aug-
mented production and increased serum levels of pro- and
anti-inﬂammatory cytokines. This unrestricted pro-inﬂammatoryvol. 61 j 1385–1396 1391
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phenotype is present in spite of persistent immune cell stimula-
tion, indicating that ‘‘endotoxin tolerance’’ is a late event in the
natural history of cirrhosis (Fig. 2). Potential explanations for this
CAID phenotype could be (i) defective production of the anti-
inﬂammatory cytokine, IL-10 [75], (ii) the non-induction of
negative feedback loops after TLR4 stimulation, such as IRAK-M
[57] or the constitutively active glycogen synthase kinase GSK3b
[113] in response to LPS, and (iii) reduced plasma high-density
lipoprotein levels and abolition of LPS downregulation of the
scavenger-receptor SR-BI in monocytes of patients with advanced
cirrhosis, since high-density lipoproteins are able to bind and
neutralize the bioactivity of LPS [114].
Finally, several lines of evidence indicate that immune
response reprogramming occurs at the further decompensated
stage of cirrhosis, after persistent LPS-driven stimulation. In the
experimental setting, intestinal dendritic cells in rats with cirrho-
sis, ascites and intense gut bacterial translocation, thus subjected
to high intestinal bacterial pressure, show decreased phagocyto-
sis and TNFa production compared with rats without bacterial
translocation, in which phagocytosis is clearly augmented [50].
In this model, bowel decontamination eliminates the bacterial
stimulus and partially normalizes intestinal dendritic cell func-
tions. This behaviour of dendritic cells could in part explain the
fact that bowel decontamination in cirrhosis improves survival
beyond mere infectious prophylaxis [115]. In the clinical setting,
severe immune response reprogramming is maximally detectable
at the very late stage of cirrhosis, i.e. in patients with acute-
on-chronic liver failure (ACLF), who develop a state of immune
paralysis that resembles that found in sepsis. This CAID pheno-
type is deﬁned by defective HLA-DR monocyte expression, the
inability of monocytes to produce TNFa in response to LPS,
reduced T lymphocyte IFNc production, and massive release of
inﬂammatory and anti-inﬂammatory (e.g. IL-10) cytokines
[116–119]. Importantly, this CAID phenotype, associated with
defective HLA-DRmonocyte expression, correlates with increased
mortality, mostly owing to bacterial infection [116–118]. Thus,
contrary to patients with ‘‘stable’’ decompensated cirrhosis,
ACLF patients exhibit a predominantly ‘‘immunodeﬁcient’’ CAID
phenotype.
In summary, under persistent PAMPs challenge, the immune
response pattern switches from a predominantly ‘‘pro-inﬂamma-
tory’’ to a predominantly ‘‘immunodeﬁcient’’ phenotype. CAID
phenotypes represent the extremes of a spectrum of reversible
dynamic events that take place during the course of cirrhosis,
though the trend is that immunodeﬁciency predominates as the
disease reaches its ﬁnal stages.
Role of systemic inﬂammation in the clinical expression of
cirrhosis
Immunodeﬁciency, coupled to systemic inﬂammation in CAID, is
the pathophysiological basis for several of the clinical
manifestations of cirrhosis. The clinical spectrum of CAID in cir-
rhosis spans from a poor response to the bacterial challenge, with
increased susceptibility to bacterial infection accompanied by
high mortality, to multi-organ inﬂammatory damage. The clinical
expression of bacteria-dependent events during cirrhosis
includes both chronic systemic and organ-speciﬁc damage and
intercurrent acute insults (i.e. acute-on-chronic) [120,121]. It
has been demonstrated that the greater the intensity of the cellu-
lar and molecular CAID, the greater the risk of severe bacterial1392 Journal of Hepatology 2014infection [84,122,123]. Speciﬁcally, the risk of bacterial infection
is greater in patients with cirrhosis and ascites who show aug-
mented serum level of molecules synthetized upon interaction
of bacteria with the host immune system, such as LBP or IgA class
anti-neutrophil cytoplasmic antibodies [122,123]. Further, the
levels of some soluble immune mediators, such as TNFR-I and
the adhesion molecule ICAM-1, are related to poor survival of
patients with cirrhosis [76,78,81]. Another manifestation of CAID
is also the non-protective response to vaccination [2,3,124].
The relevance of the systemic inﬂammation, distinctive of
CAID, stems from the fact that circulating activated immune cells
can be recruited by peripheral tissues and/or can produce soluble
factors, such as pro-inﬂammatory cytokines. Via these mecha-
nisms, inﬂammatory immune cells may damage somatic cells
and contribute to the clinical expression of cirrhosis.
A well-characterized example of the consequence of systemic
inﬂammation in the clinical expression of cirrhosis is the capacity
of high pro-inﬂammatory cytokine levels to modulate the vascu-
lar tone. These pro-inﬂammatory cytokines worsen splanchnic
and systemic vasodilation through nitric oxide overproduction
[125]. Indeed, the severity of splanchnic and peripheral vasodila-
tion is greater in patients and in experimental models of severe
cirrhosis, associated with ascites and bacterial translocation,
showing the most severe systemic inﬂammation [68,84,126].
The contribution of enteric bacteria-induced CAID to the haemo-
dynamic derangement of cirrhosis is further supported by studies
showing that selective bowel decontamination reduces nitric
oxide and plasma renin activity, and improves peripheral vasodi-
lation in patients with cirrhosis, ascites and high serum LBP
levels, and attenuates endothelial activation and expression of
inﬂammatory cytokines in the aorta of rats with biliary cirrhosis
[84,92,127].
Besides, direct signalling in the brain by pro-inﬂammatory
cytokines or recruitment of activated immune cells into brain tis-
sue, subsequently activates resident macrophages to produce
TNFa, modiﬁes cerebral function and contributes to the patho-
genesis of encephalopathy and the fatigue distinctive of cirrhosis
[128–130].
Systemic inﬂammation as well as PAMPs and DAMPs release
may also compromise kidney function [131]. Increasing evidence
indicates that inﬂammation-mediated microvascular dysfunction
can reduce glomerular ﬁltration rate, whereas the oxidative stress
that results from the organized interaction between PAMPs/
DAMPs and the tubular epithelial cell can hurt tubular function
and cause acute kidney injury in patients with severe bacterial
infection or even sepsis in the absence of overt signs of renal
hypoperfusion [132,133]. We hypothesize that pro-inﬂammatory
cytokines as well as PAMPs/DAMPs originated in the gut or other
sites of injury (i.e. liver) can gain access to the renal tubules by glo-
merular ﬁltration or by proximity to the peritubular capillaries,
and elicit an inﬂammatory response when actively recognized by
tubular epithelial cells through TLR-4, and ultimately contribute
to episodes of acute kidney injury in cirrhosis.Hypothesis
Cirrhosis-associated immune dysfunction is the result of two
concurrent and interlinked processes, namely systemic inﬂam-
mation and damage of the immune system response that come
into play as cirrhosis progresses. In the compensated pre-asciticvol. 61 j 1385–1396
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stage, DAMPs from stressed and damaged tissue, mainly necrotic
hepatocytes, activate circulating immune cells. These activation
signals add to those of the aetiologic agents of cirrhosis, such as
alcohol or viruses. Cirrhosis progression distorts hepatic architec-
ture and cellular organization and impairs its functional capacity.
These events compromise the immune surveillance function of
the liver, both locally by damaging the reticulo-endothelial
system and systemically by impairing the bactericidal role of
phagocytic cells through the reduced synthesis of proteins
involved in the innate immune response and of PRRs. In the
decompensated, ascitic stage of cirrhosis, gut bacterial
translocation occurs at a high rate and PAMPs released from
the leaky gut further activate the immune system and aggravate
systemic inﬂammation. Immune response reprogramming
occurs after constant PAMPs pressure and the predominantly
‘‘pro-inﬂammatory’’ CAID phenotype switches to the predomi-
nantly ‘‘immunodeﬁcient’’ one of severely decompensated cirrho-
sis with extra-hepatic organ failure. CAID plays a critical
pathogenetic role in several clinical manifestations of cirrhosis,
including bacterial infections, haemodynamic derangement, and
organ inﬂammatory damage, and as such has emerged as a
potential therapeutic target in cirrhosis. Identiﬁcation and grad-
ing of CAID is challenging and could be pursued by measuring
the activity of phagocytic, cytotoxic and regulatory immune cells,
their activation/anergic and differentiation stage, and serum
levels of circulating cytokines.Financial support
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